Research
Prognostic value of fibrinogen change value in adrenocortical carcinoma patients
Chengquan Ma1 . Bin Yang2 . Quanzong Mao3
Received: 8 January 2024 / Accepted: 25 July 2024
Published online: 30 July 2024
@ The Author(s) 2024 OPEN
Abstract
Purpose The aim was to explore the preoperative and postoperative fibrinogen changes value (FCV) as a prognosis biomarker for in patients with adrenocortical carcinoma (ACC).
Methods We identified 42 patients with ACC and 190 patients with adrenal adenoma (AA) who underwent surgery at our institution between 2015 and 2023. Preoperative fibrinogen, postoperative fibrinogen and follow-up information of the patients were recorded and analysed. The relationship between FCV and overall survival (OS)/ relapse-free survival (RFS) was evaluated.
Results The mean level of preoperative and postoperative fibrinogen for ACC were 4.00 ± 1.64 g/L and 2.75 ±0.59 g/L, respectively (p <0.001). The mean level of preoperative and postoperative fibrinogen for AA were 2.79±0.59 g/L and 2.71 ±0.58 g/L, respectively (p=0.144). In ACC, the lower FCV (≤1.25 g/L) showed a significantly poorer RFS than the higher (> 1.25 g/L) (p=0.007); however, the lower FCV (≤ 1.25 g/L) showed no poorer OS than the higher (> 1.25 g/L) (p=0.243). On multivariate survival analyses, FCV remained a predictor of RFS (HR 3.138).
Conclusion According to the data in this study, it can be said that FCV is correlated with prognosis of ACC. The FCV might be a new biomarker for predicting the RFS of ACC.
Keywords Fibrinogen changes value · Adrenocortical carcinoma · Adrenal adenoma
1 Introduction
Adrenocortical carcinoma (ACC) is a rare malignancy with an incidence rate of about 0.7-2 per million per year [1]. Due to the insidious onset of ACC, the disease usually (over half of the patients) does not cause any clinical symptoms until it advances into progressive stages. Most patients with ACC have a poor prognosis, the expected 5-year survival rate of stage I patients is 80%, whereas that of stage IV patients is only 13% [2]. Even stage I to III tumors in patients with tumors after surgical treatment still have a high risk of recurrence, more than 50% of patients with ACC will develop recurrence within 5 years [3]. Mitotane can be used as an initial treatment for patients with ACC who have no surgical opportunity or cannot completely remove the tumor. Jason A Glenn conducted a retrospective review of 576 patients with adreno- cortical carcinoma underwent resection of stage I-III adrenocortical carcinoma, found that 70% of patients developed disease recurrence [4].
☒ Chengquan Ma, machengquan@tmu.edu.cn; machqu163@163.com | 1Department of Urology, Tianjin Medical University General
Hospital, No 154. Anshan Road, Tianjin 300052, China. 2Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. 3Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Check for updates
(2024) 15:320
| https://doi.org/10.1007/s12672-024-01197-5
Discover
There may be a variety of disorders in the body of cancer patients, especially inflammation, abnormal coagulation, abnormal nutrient consumption and so on. The relevant serological indicators indicate these disorders and reflect the body status of cancer patients. These include elevated plasma fibrinogen levels that reflect the inflammatory and clot- ting responses present in tumor patients that are associated with tumor progression. Fibrinogen is a key glycoprotein produced by the liver that functions as a non-specific acute phase reactant and is involved in inflammatory responses, clotting pathways, and tumor formation. Fibrinogen is involved in the proliferation and metastasis of malignant tumors by participating in the composition of extracellular matrix in the tumor microenvironment, being recognized by various integrins, activating the coagulation system and promoting the metastasis of circulating tumor cells [5].
Previous studies have used preoperative blood tests (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, red blood cell distribution width, mean platelet volume and plateletcrit) to predict the outcome of patients with ACC [6-8]. A large number of studies have raised the possibility of fibrinogen as a valuable marker for detecting cancer, informing prognoses, and monitoring treatment responses [9-11]. In a retrospective analysis of penile cancer, Ma et al. found that preoperative fibrinogen levels can be used as an independent prognostic marker to predict patient survival outcomes [12]. Masaaki Yamamoto et al. found that preoperative plasma fibrinogen level had the highest predictive value for recurrence among seven known hematological prognostic markers, and it would be useful for predicting prognosis after gastric cancer surgery [13]. However, the correlation between the postoperative fibrinogen changes and ACC is currently unknown. No studies have evaluated whether FCV predicts RFS and OS in postoperative ACC. In this study, we investigated the correlation between fibrinogen changes value (FCV) and ACC.
2 Methods
We retrospectively evaluated the data of 42 patients with ACC and 190 patients with AA who underwent resection at Tianjin Medical University General Hospital and Peking Union Medical College Hospital between January 1, 2015 and January 1, 2023. Tumors were graded according to the Union for International Cancer Control TNM staging system. All pertinent laboratory, pathological results and medical data were obtained from hospital databases. Data obtained from patients’ routine preoperative or postoperative test results included plasma fibrinogen, age, sex, BMI, type of surgery, marginal condition, mitotane-based specific chemotherapy, R status and ki-67 index. Fibrinogen change value = pre- operative fibrinogen level (within a week before surgery) minus postoperative fibrinogen level (1 month after surgery). Patients with coexisting hematologic diseases and those in the inflammatory phase were excluded. All patients with AA were nonfunctional adenomas. Within the preoperative fibrinogen and postoperative fibrinogen comparison, data obtained from the AA and ACC groups were evaluated using the t-test. The Kaplan-Meier product limit estimator was used to estimate the RFS and OS. A log-rank test was performed for comparison. For multivariate analysis, the Cox regres- sion model was applied. The mean FCV was used to evaluate the prognostic RFS/OS relationship between fibrinogen change value and ACC.
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp, Armonk, NY). Sta- tistical significance was set at p < 0.05.
3 Results
Data from the 232 cases is presented in Table 1 (including the levels of fibrinogen, gender, age, BMI, and stage infor- mation). ACC consisted of 42 patients, with the diameter ranging from 3.3 cm to 19.2 cm and an average diameter of 6.42 ±3.90 cm. While AA consisted of 190 patients, with the diameter ranging from 1.2 cm to 5.0 cm and an average diameter of 2.11 ±0.60 cm.
The mean levels of preoperative and postoperative fibrinogen for ACC were 4.00 ± 1.64 g/L and 2.75 +0.59 g/L, respec- tively (p <0.001). The mean FCV was 1.25 g/L. The mean level of preoperative and postoperative fibrinogen for AA were 2.79±0.59 g/L and 2.71+0.58 g/L, respectively (p=0.144).
Patients with FCV ≤ 1.25 g/L had a higher tumor stage (p=0.03), higher Ki-67 index (p=0 0.005) compared to the patients with FCV > 1.25 g/L (Table 2).
Discover
| Groups | ACC | AA |
|---|---|---|
| Number of cases | 42 | 190 |
| Gender | ||
| Male | 22 | 91 |
| Female | 20 | 99 |
| Age (mean, years) | 62.93±5.37 | 55.97 ±11.36 |
| BMI (mean, kg/m2) | 24.68 ±2.26 | 25.74±4.99 |
| Preoperative fibrinogen (mean, g/L) | 4.00±1.64 | 2.79±0.59 |
| Postoperative fibrinogen (mean, g/L) | 2.75±0.59 | 2.71 ±0.58 |
ACC adrenocortical carcinoma, AA adrenal adenoma
| Variable | FCV> 1.25 (20 cases) | FCV ≤ 1.25 g/L (22 cases) | P value |
|---|---|---|---|
| Age (year) | 62.13±5.07 | 63.22±5.42 | 0.43 |
| Gender (female/male) | 9/11 | 10/12 | 0.69 |
| BMI | 24.32±2.23 | 24.77±2.30 | 0.32 |
| Tumor size (mm) | 94 (35-192) | 83 (33-140) | 0.28 |
| Tumor stage (n, %) | |||
| I-II | 17 | 12 | 0.03 |
| III-IV | 3 | 10 | |
| Excess glucocorticoid secretion | 9 (45) | 14 (64) | 0.23 |
| (n, %) | |||
| Ki-67>10% (%) | 8 (40) | 18 (82) | 0.005 |
FCV fibrinogen changes value
At the time of last follow-up, 14 (35%) patients had developed recurrent disease after a median RFS of 63.41 months. For patients with FCV ≤ 1.25 g/L, the 5-year RFS was 25.0% and the 5-year OS was 33.3%. For patients with FCV > 1.25 g/L, the 5-year RFS was 90.9% and the 5-year OS was 61.6%.
In ACC, the lower FCV (≤1.25 g/L) showed a significantly poorer RFS than the higher (> 1.25 g/L) (Fig. 1; p=0.007); however, the lower FCV (≤ 1.25 g/L) showed no poorer OS than the higher (> 1.25 g/L) (Fig. 2; p= 0.243).
On multivariate survival analyses, tumor stage (HR 1.830, 95%CI 1.046-3.77), margin status (HR 1.501, 95%CI 1.210-4.063), Ki-67> 10% (HR 2.125,95%CI 1.632 ~4.089) post-operative chemotherapy without mitotane (HR 1.620, 95%CI 1.133-7.125) as well as low FCV (HR 3.138, 95%CI 2.53-7.962) remained independent predictors of a shorter RFS (all P <0.05; Table 3).
4 Discussion
Many previous studies have found correlations between preoperative fibrinogen levels and the clinicopathology and prognosis of tumors” for clearer expression. Generally, the higher the preoperative fibrinogen level, the more malig- nant the tumors and the worse the prognosis. Then, if fibrinogen is high before surgery, will the prognosis of signifi- cantly reduced after surgery be better? This article mainly answers this question. This study confirms these important findings. First, the mean postoperative fibrinogen was significantly lower than preoperative in ACC (2.75 ± 0.59 g/L vs. 4.00± 1.64 g/L, p <0.001). The mean postoperative fibrinogen was not significantly lower than preoperative in AA (2.71 ±0.58 g/L vs. 2.79±0.59 g/L, p=0.144). The cutoff value of FCV is estimated as 1.25 g/L. Elevated FCV is associated with better RFS. To our knowledge, this is the first study to consider the correlation between the FCV and ACC.
A major clinical feature of ACC is easy recurrence and poor prognosis, and the recurrence of ACC after surgery is mainly related to the late stage of the tumor and the surgical technique. If surgical resection of locally advanced ACC patients can be performed according to the principle of RO resection, if necessary, the adjacent organs that may be involved should be excised together, which may reduce the probability of local recurrence. Misperception of adrenal
Discover
Fibrinogen change value ≤1.25
Fibrinogen change value>1.25
Censored value
☒ Censored value
1.0
0.8
Proportion surviving recurrence-free
0.6
0.4
☒
0.2
0.0
0
20
40
60
80
100
120
Time (months)
benign tumor before operation and failure to observe the principle of no tumor during operation will increase the risk of local recurrence after operation. The latest guidelines are the preferred open surgery for ACC surgery. For the failure to accurately determine ACC before surgery, minimally invasive surgical treatment, intraoperative tumor rupture, or failure to achieve R0 resection, is the important cause of local recurrence [14]. The reasons about ACC patients with a high risk for recurrence were explored, such as a ruptured capsule, large size or high-grade histology [15-17]. In patients without recurrence who tolerate mitotane therapy, it is recommended to administer the drug for at least 2 years [18] and up to 5 years [19]. It is difficult to determine whether the therapeutic benefits result from mitotane alone. In a meta-analysis including 6 retrospective studies, mitotane therapy resulted in improved mortality but not decreased recurrence [19].
In recent years, the relationship between hypercoagulability and malignant tumor progression has attracted exten- sive attention. Plasma fibrinogen is the main protein substance in the process of human coagulation. The coagulation function of malignant tumor patients is enhanced and the body is in a state of hypercoagulation, which makes it easy to form thrombosis. The fibrin principle plays an important role in inflammation and blood agglutination reactions. The formation and structural stability of fibrinogen are not only affected by individual genetics, environment, coagulation, thrombosis, pregnancy, inflammatory response, infection, diabetes, hypertension and other factors, but also have a certain relationship with the progression and prognosis of various malignant tumors.
Recent studies have shown that fibrinogen and pancreatic cancer [20], prostate cancer [21], laryngeal squamous cell carcinoma [22], renal cell carcinoma [23], endometrial cancer [24], penile cancer [24], small cell lung cancer [25], liver cancer [26], liposarcoma [27] and other tumors were related to the development or prognosis. This study found that preoperative plasma fibrinogen levels and postoperative fibrinogen changes have important value for the prognosis of ACC patients.
Fibrinogen is an essential landmark protein in the process of blood coagulation in the human body, and an acute- phase reactant in the inflammatory environment. It promotes the synthesis of pro-inflammatory cytokines, and the change of fibrinogen level can indicate systemic inflammation. It can also accumulate at the tumor site to form high expression and affect tumor progression [28]. Elevated fibrinogen plasma levels may be the result of hypercoagulability
Discover
Fibrinogen change value ≤1.25
“Fibrinogen change value>1.25
Censored value
☒ Censored value
1.0
0.8
Proportion surviving
0.6
0.4
☒
0.2
0.0
0
20
40
60
80
100
120
Time (months)
| Parameters | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Gender (female vs male) | 0.406 | 0.156-1.230 | 0.09 | |||
| Age (>62.93vs ≤62.93) | 0.995 | 0.726-2.619 | 0.987 | |||
| BMI (>24.68vs ≤24.68) | 1.042 | 0.993 - 1.024 | 0.693 | |||
| Excess glucocorticoid secretion (yes vs no) | 3.46 | 1.992-9.302 | 0.010 | 1.442 | 0.946-8.720 | 0.061 |
| Tumor stage (III-IV vs I-II) | 2.167 | 1.192-6.398 | 0.012 | 1.830 | 1.046-3.771 | 0.026 |
| Margin status (no-R0 vs R0) | 1.647 | 1.542-9.07 | 0.019 | 1.501 | 1.210-4.063 | 0.029 |
| Post-operative chemotherapy (no vs yes) | 1.381 | 0.925-2.042 | 0.642 | |||
| Ki-67> 10% (yes vs no) | 2.691 | 2.232-5.002 | 0.010 | 2.125 | 1.632-4.089 | 0.018 |
| Post-operative chemotherapy with mitotane (no vs yes) | 2.724 | 1.457 - 12.809 | 0.011 | 1.620 | 1.133-7.125 | 0.021 |
| FCV (≤1.25 vs F> 1.25) | 5.025 | 3.627 - 13.822 | 0.007 | 3.138 | 2.53-7.962 | 0.009 |
Bold values indicate statistically significant
FCV fibrinogen changes value
and hypoxia induced by tumor growth [29], may be the result of tumor cells themselves [30], or may be the result of inflammation mediating the cell as a host response to the tumor [31]. The possible mechanisms are as follows: (1) Fibrinogen can increase blood viscosity and peripheral resistance, promote red blood cell adhesion and thrombosis [32]; (2) Fibrinogen promotes tumor cell growth and angiogenesis through interaction with fibroblast growth factor-2
Discover
and vascular endothelial growth factor [32]. (3) Plasma fibrinogen is mainly produced in the liver through the activation of inflammatory cytokines interleukin-6 (IL-6) and IL-10 [33]. High plasma fibrinogen levels in patients may be related to excessive levels of inflammatory factors caused by tumors; (4) Fibrinogen may induce functional changes of stromal cells and inflammatory cells by integrating related cells, and promote cell proliferation and migration [34]. Previous studies have described the mechanism of hyperfibrinogenemia in patients with malignant tumors [35, 36]. Malignant cells typically have high levels of a fibrinogen receptor called intercellular adhesion molecule 1, and platelets also have a fibrinogen receptor called aIIb3 integrin. Malignant cells bind to platelets via fibrinogen. These aggregates form tumor clots that bind to the endothelium at the original site of the adrenal gland, adjacent tissues, and other organs and hide in the target organ to avoid immune system attack. Through this mechanism, fibrinogen plays a role in tumor progres- sion, recurrence, and metastasis.
There are several restrictions on this study. First, because this study was retrospective in nature, it is unable to analyze attributable variables because of recollection bias. Second, it was known that prolonged exposure to high glucocorticoid levels affects fibrinogen quantities and function, potentially mimicking tumor-associated inflammatory reactions. Our results could have been affected to some extent by the tumor’s functional state and the resultant glucocorticoid over- production. Third, since there are several variables that have a significant impact on the levels of systemic coagulation markers, even slight changes in these values might have an impact on prognostic evaluation. We anticipate that addi- tional extensive and comprehensive patient investigations might more precisely demonstrate the relationship between FCV and the prognosis of ACC.
Acknowledgements Not applicable.
Author contributions Chengquan Ma designed and wrote the study; Chengquan Ma and Quanzong Mao were involved with the conception of the analyses; Chengquan Ma and Bin Yang were involved with performing the analyses; and all authors were involved with interpretation of the data. Chengquan Ma wrote the paper. All authors provided their approval for the final version to be published. All authors agreed to be accountable for the accuracy and integrity of the work.
Funding This work was supported by Scientific Research Project of Tianjin Municipal Education Commission (No.2023KJ115).
Data availability The data could not be shared on open access; If needed during the review process, we could provide the datasets to the editor or editorial staff upon request (Chengquan Ma; machengquan@tmu.edu.cn).
Declarations
Ethics approval and consent to participate The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments, and local ethical approval was obtained from the Ethics Committee of the Peking Union Medical College Hospital and Tianjin Medical University General Hospital.
Consent for publication Consent for publication was obtained from all individual participants included in the study.
Competing interests All authors declare they have no competing of interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adapta- tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Libe R, Huillard O. Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37:100759. https://doi.org/10.1016/j.ctarc.2023.100759.
2. Lafemina J, Brennan MF. Adrenocortical carcinoma: past, present, and future. J Surg Oncol. 2012;106(5):586-94. https://doi.org/10.1002/ jso.23112.
3. Kiseljak-Vassiliades K, Bancos I, Hamrahian A, Habra M, Vaidya A, Levine AC, Else T. American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach. Endocr Pract. 2020;26(11):1366-83. https://doi.org/10.4158/DSCR-2020-0567.
Discover
| https://doi.org/10.1007/s12672-024-01197-5
4. Glenn JA, Else T, Hughes DT, Cohen MS, Jolly S, Giordano TJ, Worden FP, Gauger PG, Hammer GD, Miller BS. Longitudinal patterns of recur- rence in patients with adrenocortical carcinoma. Surgery. 2019;165(1):186-95. https://doi.org/10.1016/j.surg.2018.04.068.
5. He SS, Wang Y, Yang L, Chen HY, Liang SB, Lu LX, Chen Y. Plasma fibrinogen correlates with metastasis and is associated with prognosis in human nasopharyngeal carcinoma. J Cancer. 2017;8(3):403-9. https://doi.org/10.7150/jca.17028.
6. Gaitanidis A, Wiseman D, El Lakis M, Nilubol N, Kebebew E, Patel D. Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma. J Surg Oncol. 2019;120(8):1450-5. https://doi.org/10.1002/jso.25760.
7. de Jong MC, Mihai R, Khan S. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as possible prognostic markers for patients undergoing resection of adrenocortical carcinoma. World J Surg. 2021;45(3):754-64. https://doi.org/10.1007/ s00268-020-05868-6.
8. Sisman P, Bicer B, Gul OO, Cander S, Ersoy C, Saraydaroglu O, Erturk E. May hemocytometer parameters be a biomarker in distinguishing between adrenal adenomas and carcinomas and in prognosis of adrenocortical carcinomas? Acta Clin Croat. 2020;59(3):439-44. https:// doi.org/10.20471/acc.2020.59.03.07.
9. Zhu LR, Li J, Chen P, Jiang Q, Tang XP. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol. 2016;18(2):178-88. https://doi.org/10.1007/s12094-015-1350-7.
10. Yuan C, Huang M, Wang H, Jiang W, Su C, Zhou S. Pretreatment fibrinogen-albumin ratio (FAR) associated with treatment response and survival in advanced non-small cell lung cancer patients treated with first-line anti-PD-1 therapy plus platinum-based combination chemotherapy. Cancer Manag Res. 2022;14:377-86. https://doi.org/10.2147/CMAR.S347547.
11. Yu W, Bao L, Qian Z, Wang D. Neutrophil-lymphocyte ratio combined with plasma fibrinogen is an useful predictor for the diagnosis of liver metastases from gastric cancer. Asian J Surg. 2022;45(11):2378-9. https://doi.org/10.1016/j.asjsur.2022.05.058.
12. Ma C, Zhou Y, Zhou S, Zhao K, Lu B, Sun E. Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in penile cancer. Oncotarget. 2017;8(7):12355-63. https://doi.org/10.18632/oncotarget.12563.
13. Yamamoto M, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Usefulness of preopera- tive plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence. World J Surg. 2016;40(8):1904-9. https:// doi.org/10.1007/s00268-016-3474-5.
14. Schimmack S, Strobel O. Resection strategies for adrenocortical carcinoma. Chirurg. 2019;90(1):9-14. https://doi.org/10.1007/ s00104-018-0712-4.
15. Kreissl MC, Bastholt L, Elisei R, Haddad R, Hauch O, Jarzab B, Robinson B, Colzani R, Foster M, Weiss R, Schlumberger M. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial. J Clin Oncol. 2020;38(24):2773-81. https://doi.org/10.1200/JCO.19.02790.
16. Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R, Carling T, Backdahl M, Wang N, Juhlin CC, Larsson C. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. Int J Mol Med. 2018;42(3):1675-83. https://doi.org/10. 3892/ijmm.2018.3735.
17. Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, Soon PS, Sidhu SB. Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocr Relat Cancer. 2015;22(1):99-109. https://doi.org/10.1530/ERC-14-0457.
18. Basile V, Puglisi S, Altieri B, Canu L, Libe R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M. What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. J Pers Med. 2021;11(4):5. https://doi.org/10.3390/jpm11040269.
19. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018;179(4):G1-46. https://doi.org/10.1530/EJE-18-0608.
20. Igarashi Y, Shirai Y, Tanji Y, Hamura R, Yanagaki M, Abe K, Onda S, Furukawa K, Matsumoto M, Tsunematsu M, Ikegami T. The impact of fibrinogen to prognostic nutritional index rate on prognosis of pancreatic ductal adenocarcinoma. Am Surg. 2023. https://doi.org/10. 1177/00031348231204912.
21. Lei X, Zhang T, Deng Z, Jiang T, Hu Y, Yang N. Coagulation markers as independent predictors of prostate cancer aggressiveness: a retro- spective cohort study. Sci Rep. 2023;13(1):16073. https://doi.org/10.1038/s41598-023-43427-w.
22. Huang Q, Chen J, Huang Y, Xiong Y, Zhou J, Zhang Y, Lu M, Hu W, Zheng F, Zheng C. The prognostic role of coagulation markers in the pro- gression and metastasis of laryngeal squamous cell carcinoma. BMC Cancer. 2023;23(1):901. https://doi.org/10.1186/s12885-023-11381-5.
23. Sekito S, Tanaka S, Kitano G, Kato M, Ogura Y, Kojima T. Pre-operative plasma fibrinogen level as a potential predictor of pathological T3 upstaging in clinically localized renal cell carcinoma. Anticancer Res. 2023;43(9):4229-35. https://doi.org/10.21873/anticanres.16615.
24. Li H, Liao H, Jing B, Wang Y. Effects of coagulation function indicators and tumor markers on diagnosis and clinicopathological charac- teristics of endometrial cancer. Int J Biol Markers. 2023. https://doi.org/10.1177/03936155231196253.
25. Tian J, Tian H, Yang M, Yang L, Liu D. Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: a cross-sectional study. Health Sci Rep. 2023;6(8): e1507. https://doi.org/10.1002/hsr2.1507.
26. Qian X, Cai J, Qi Q, Han J, Zhu X, Xia R, Zhang Q. Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway. Heliyon. 2023;9(6): e16696. https://doi.org/10.1016/j. heliyon.2023.e16696.
27. Peschek LS, Hobusch GM, Funovics PT, Willegger M, Schmid MP, Amann G, Lamm W, Brodowicz T, Ay C, Windhager R, Panotopoulos J. High fibrinogen levels are associated with poor survival in patients with liposarcoma. Sci Rep. 2023;13(1):8608. https://doi.org/10.1038/ s41598-023-31527-6.
28. Miyazaki T, Nagayasu T. Editorial on “Albumin-to-fibrinogen ratio as a prognostic biomarker to predict clinical outcome of non-small cell lung cancer individuals.” J Thorac Dis. 2019;11(Suppl 9):S1241-4. https://doi.org/10.21037/jtd.2019.03.02.
29. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-9.
30. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost. 2008;6(1):176-83. https://doi.org/10.1111/j.1538-7836.2007.02808.x.
Discover
31. Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflam- mation. Thromb Haemost. 2004;92(2):234-43. https://doi.org/10.1160/TH04-01-0024.
32. Wolberg AS. Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition. Curr Opin Hematol. 2018;25(5):358-64. https://doi.org/10.1097/MOH.0000000000000445.
33. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 2005;24(45):6848-54. https:// doi.org/10.1038/sj.onc.1208815.
34. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952-6. https://doi.org/10. 1038/sj.bjc.6605547.
35. Liu X, Shi B. Progress in research on the role of fibrinogen in lung cancer. Open Life Sci. 2020;15(1):326-30. https://doi.org/10.1515/ biol-2020-0035.
36. Madani M, Goldstein D, Stefanescu R, Woodman SE, Rojas-Hernandez CM. Characterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patients. Cancer Med. 2022;11(20):3771-85. https:// doi.org/10.1002/cam4.4753.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Discover